Table 1 Demographic and clinical data and antibody reactivity of patients included in this study according to the human MOG antibody status
hMOG antibody negativea | hMOG antibody positivea | P value | |
|---|---|---|---|
Number of patients/samples | 20 | 80 | |
hMOG antibody titer [1:]b | 1280 (160–20,480) | ||
Females | 9 (45%) | 37 (46%) | 0.999c |
Age (years)b | 12.4 (3.5–44.8) | 7.0 (0.2–71.1) | 0.020d |
Pediatric patients | 15 (75%) | 69 (83%) | 0.303c |
Disease duration (years)b | 0.3 (0–19.7) | 0.1 (0–15.4) | 0.038d |
Clinical diagnosis at sampling: | |||
ADEM | 11 (55%) | 37 (46%) | < 0.001e |
CIS-ON | 0 (0%) | 13 (16%) | |
CIS-LETM | 1 (5%) | 5 (6%) | |
CIS-multifocal | 0 (0%) | 2 (3%) | |
MDEM | 0 (0%) | 4 (5%) | |
NMOSD | 1 (5%) | 12 (15%) | |
Recurrent ON | 0 (0%) | 7 (9%) | |
MS | 7 (35%) | 0 (0%) | |
Recurrent course at sampling | 7 (35%) | 17 (21%) | 0.243c |
Reactive with mouse MOGa | 0 (0%) | 48 (60%) | < 0.001c |
Median titer (range) | 640 (160–20,480) | ||
Reactive with rat MOGa | 0 (0%) | 14 (18%) | 0.066c |
Median titer (range) | 1280 (160–5120) | ||
Reactivity with brain tissue: | |||
Antibody binding to human myelin | 0 (0%) | 70 (88%) | < 0.001c |
Antibody binding to mouse myelin | 1 (5%) | 27 (34%) | 0.011c |
Thereof mMOG reactive | 0/1 (0%) | 25/27 (93%) | |
Thereof rMOG reactive | 0/1 (0%) | 11/27 (41%) | |
Therof mMOG or rMOG reactive | 0/1 (0%) | 25/27 (93%) | |
Antibody binding to rat myelin | 4 (20%) | 24 (30%) | 0.578c |
Thereof mMOG reactive | 0/4 (0%) | 23/24 (96%) | |
Thereof rMOG reactive | 0/4 (0%) | 14/24 (58%) | |
Therof mMOG or rMOG reactive | 0/4 (0%) | 23/24 (96%) | |